mitomycin has been researched along with Cancer of the Ureter in 39 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C." | 7.68 | Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ. ( Amano, T; Hisazumi, H; Koshida, K; Kunimi, K; Morishita, H; Naito, K, 1993) |
| " Bleeding, infection, and fever were most common with adjuvant treatment (BCG or mitomycin)." | 5.12 | Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma. ( Linehan, J; Schoenberg, M; Seltzer, E; Smith, AB; Thacker, K, 2021) |
| "We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C." | 3.68 | Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ. ( Amano, T; Hisazumi, H; Koshida, K; Kunimi, K; Morishita, H; Naito, K, 1993) |
| " Protocol variability and dosage differences limit statistical interpretation." | 2.72 | Nephron-sparing management of upper tract urothelial carcinoma. ( Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP, 2021) |
| "A recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract is not rarely observed." | 2.70 | Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. ( Ariyoshi, A; Fujisawa, Y; Kumazawa, J; Morita, I; Naito, S; Omoto, T; Osada, Y; Sakamoto, N; Yamashita, H, 2001) |
| " Ureteral stenosis and other adverse events were abstracted from the medical records." | 1.91 | Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. ( Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.26) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 2 (5.13) | 29.6817 |
| 2010's | 16 (41.03) | 24.3611 |
| 2020's | 13 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, GH | 1 |
| Nallani, A | 1 |
| Muzzey, C | 1 |
| Murray, KS | 5 |
| Kim, SH | 1 |
| Lerner, SP | 1 |
| Rose, KM | 1 |
| Narang, G | 1 |
| Rosen, G | 1 |
| Labatte, C | 1 |
| Dumitrascu, CI | 1 |
| Campagna, J | 1 |
| Yu, A | 1 |
| Manley, BJ | 1 |
| Spiess, PE | 1 |
| Li, R | 1 |
| Adibi, M | 1 |
| Sexton, WJ | 1 |
| Humphreys, MR | 1 |
| Woldu, SL | 3 |
| Labbate, C | 5 |
| Rose, K | 5 |
| Sexton, W | 5 |
| Tachibana, I | 5 |
| Kaimakliotis, H | 4 |
| Jacob, J | 5 |
| Dickstein, R | 5 |
| Linehan, J | 6 |
| Nieder, A | 5 |
| Bjurlin, MA | 3 |
| Humphreys, M | 5 |
| Ghodoussipour, S | 5 |
| Quek, ML | 3 |
| O'Donnell, M | 5 |
| Eisner, BH | 4 |
| Feldman, AS | 4 |
| Matin, SF | 8 |
| Lotan, Y | 6 |
| Woldu, S | 3 |
| Murray, K | 2 |
| Bjurlin, M | 2 |
| Quek, M | 2 |
| Eisner, B | 1 |
| Feldman, A | 1 |
| van Wijngaarden, C | 1 |
| Bus, MTJ | 1 |
| Ruiter, AEC | 1 |
| Lagerveld, BW | 1 |
| Song, S | 1 |
| Smith, A | 1 |
| Hu, B | 1 |
| Kaimakliotis, HZ | 1 |
| Okeke, Z | 2 |
| Rai, A | 1 |
| Territo, A | 1 |
| Gallioli, A | 1 |
| Breda, A | 1 |
| Freifeld, Y | 1 |
| Ghandour, R | 1 |
| Singla, N | 1 |
| Bagrodia, A | 1 |
| Rapoport, LM | 1 |
| Gazimiev, M | 1 |
| Delafuente, K | 1 |
| Kulangara, R | 1 |
| Robyak, H | 1 |
| Petros, FG | 1 |
| Raman, JD | 3 |
| Margulis, V | 1 |
| Schoenberg, M | 1 |
| Seltzer, E | 1 |
| Thacker, K | 1 |
| Smith, AB | 1 |
| Farrow, JM | 1 |
| Kern, SQ | 1 |
| Gryzinski, GM | 1 |
| Sundaram, CP | 1 |
| Metcalfe, M | 1 |
| Wagenheim, G | 2 |
| Xiao, L | 2 |
| Papadopoulos, J | 2 |
| Navai, N | 2 |
| Davis, JW | 2 |
| Karam, JA | 2 |
| Kamat, AM | 2 |
| Wood, CG | 2 |
| Dinney, CP | 2 |
| Somani, BK | 1 |
| Balasubramanian, A | 1 |
| Metcalfe, MJ | 1 |
| Ubrig, B | 1 |
| Roth, S | 1 |
| Boy, A | 1 |
| Rouprêt, M | 3 |
| Babjuk, M | 2 |
| Compérat, E | 1 |
| Zigeuner, R | 2 |
| Sylvester, RJ | 1 |
| Burger, M | 1 |
| Cowan, NC | 1 |
| Böhle, A | 1 |
| Van Rhijn, BW | 1 |
| Kaasinen, E | 2 |
| Palou, J | 2 |
| Shariat, SF | 1 |
| Shibing, Y | 1 |
| Qiang, W | 1 |
| Motamedinia, P | 1 |
| Keheila, M | 1 |
| Leavitt, DA | 1 |
| Rastinehad, AR | 1 |
| Smith, AD | 1 |
| Lu, DD | 1 |
| Boorjian, SA | 2 |
| Wu, WJ | 1 |
| Ke, HL | 1 |
| Yang, YH | 1 |
| Li, CC | 1 |
| Chou, YH | 1 |
| Huang, CH | 1 |
| Nieder, AM | 1 |
| O'Brien, T | 1 |
| Ray, E | 1 |
| Singh, R | 1 |
| Coker, B | 1 |
| Beard, R | 1 |
| Boehle, A | 1 |
| Sylvester, R | 1 |
| Oosterlinck, W | 1 |
| Goel, A | 1 |
| Paul, S | 1 |
| Smith, P | 1 |
| Mandel, J | 1 |
| O'Donoghue, JP | 1 |
| Crew, JP | 1 |
| Fujihiro, S | 1 |
| Takeuchi, T | 1 |
| Fujimoto, Y | 1 |
| Okano, M | 1 |
| Horie, M | 1 |
| Kanematsu, M | 1 |
| Kuriyama, M | 1 |
| Ban, Y | 1 |
| Nishiura, T | 1 |
| Eastham, JA | 1 |
| Huffman, JL | 1 |
| Amano, T | 1 |
| Naito, K | 1 |
| Koshida, K | 1 |
| Kunimi, K | 1 |
| Morishita, H | 1 |
| Hisazumi, H | 1 |
| Seaman, EK | 1 |
| Slawin, KM | 1 |
| Benson, MC | 1 |
| Sakamoto, N | 1 |
| Naito, S | 1 |
| Kumazawa, J | 1 |
| Ariyoshi, A | 1 |
| Osada, Y | 1 |
| Omoto, T | 1 |
| Fujisawa, Y | 1 |
| Morita, I | 1 |
| Yamashita, H | 1 |
| Uekado, Y | 1 |
| Hirano, A | 1 |
| Shinka, T | 1 |
| Ohkawa, T | 1 |
| Eldrup, J | 1 |
| Jess, P | 1 |
| Palm, L | 1 |
| van Helsdingen, PJ | 1 |
| Rikken, CH | 1 |
| Smith, AY | 1 |
| Vitale, PJ | 1 |
| Lowe, BA | 1 |
| Woodside, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
4 reviews available for mitomycin and Cancer of the Ureter
| Article | Year |
|---|---|
Drug instillation in the management of urinary tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Instillation, Drug; Kidney; Mitomycin; Neoplasm Recurrence, Lo | 2022 |
Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Fever; Humans; Incidence; Kidney | 2021 |
Nephron-sparing management of upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2021 |
Treatment options for upper tract transitional-cell carcinoma.
Topics: Administration, Topical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Human | 1993 |
3 trials available for mitomycin and Cancer of the Ureter
| Article | Year |
|---|---|
Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neopl | 2011 |
Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, | 2001 |
Results of adjuvant chemotherapy for invasive uroepithelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1992 |
32 other studies available for mitomycin and Cancer of the Ureter
| Article | Year |
|---|---|
Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Topics: Carcinoma, Transitional Cell; Female; Humans; Hydrogels; Kidney Neoplasms; Male; Mitomycin; Ureteral | 2022 |
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
Topics: Carcinoma, Transitional Cell; Constriction, Pathologic; Humans; Mitomycin; Nephrostomy, Percutaneous | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Constriction, Pathologic; Humans; Kidney Neopl | 2023 |
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Neoplasm Recurrence, Local; Nephroureterectomy; Ret | 2023 |
The patient experience with localized upper tract urothelial cancer.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Patient Outco | 2023 |
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Nephrons; Retrospective Studies; | 2023 |
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Prospective Studies; Ureteral Neoplasms; Ureterosco | 2020 |
Response to Okeke and Rai:"Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Center Prospective Nonrandomized Trial" by Gallioli et al.
Topics: Carcinoma, Transitional Cell; Humans; Mitomycin; Prospective Studies; Ureteral Neoplasms; Ureterosco | 2020 |
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2020 |
Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemothera | 2017 |
Editorial Comment on: Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes by Metcalfe et al.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplas | 2017 |
Salvage topical therapy for upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG | 2018 |
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Function Tests; Kidney Ne | 2018 |
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherap | 2015 |
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Topics: Adjuvants, Immunologic; Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BC | 2016 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2010 |
Editorial comment.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2010 |
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet?
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2011 |
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
Topics: BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnostic Ima | 2012 |
Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospecti
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2012 |
Conservative nephron-sparing treatment of upper-tract tumors.
Topics: Administration, Topical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chemother | 2013 |
Adjuvant topical treatment of upper urinary tract urothelial tumours.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2004 |
[Chemotherapy of urothelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; | 1984 |
Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Instillati | 1993 |
Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Cisplatin; Doxorubicin; Humans; M | 1993 |
[Intrapelvic instillation of mitomycin C in the treatment of ureteral tumor in a patient with a single kidney].
Topics: Humans; Male; Middle Aged; Mitomycin; Mitomycins; Nephrectomy; Papilloma; Pelvic Neoplasms; Ureter; | 1986 |
Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop.
Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Ileum; Kidney Neoplasms; Male | 1986 |
Treatment of superficial papillary transitional cell carcinoma of the ureter by vesicoureteral reflux of mitomycin C.
Topics: Administration, Intravesical; Aged; Carcinoma in Situ; Carcinoma, Transitional Cell; Humans; Male; M | 1987 |